First Trust Advisors LP Purchases 189,245 Shares of Krystal Biotech, Inc. $KRYS

First Trust Advisors LP boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 571.3% during the 2nd quarter, Holdings Channel reports. The fund owned 222,370 shares of the company’s stock after buying an additional 189,245 shares during the period. First Trust Advisors LP’s holdings in Krystal Biotech were worth $30,567,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Edgestream Partners L.P. purchased a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $2,705,000. State of New Jersey Common Pension Fund D raised its stake in Krystal Biotech by 45.2% in the second quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after buying an additional 4,682 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in Krystal Biotech during the first quarter worth $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares in the last quarter. Finally, S Squared Technology LLC increased its holdings in shares of Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock valued at $17,528,000 after acquiring an additional 2,000 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $239.72 on Thursday. The company has a market cap of $6.95 billion, a price-to-earnings ratio of 35.94 and a beta of 0.48. The stock’s fifty day moving average price is $201.43 and its 200 day moving average price is $165.04. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $241.85.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. Research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Chardan Capital upped their price objective on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Bank of America increased their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Finally, Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).